



— 2025 —

DEBATES AND DIDACTICS
in **Hematology**
and **Oncology**



Where **Science** Becomes **Hope**

JULY 24 - 27, 2025 • SEA ISLAND, GEORGIA

This activity is jointly provided by





Early vs Delayed Transplantation in Myelofibrosis: **DELAYED**

Michael J. Hochman, MD

Assistant Professor of Hematology




Emory University School of Medicine

Atlanta, GA


Relevant Disclosures

- Rigel Pharmaceuticals (ad board, honoraria)
- Not a transplanter
- Also not Harry Potter

Not Too Early, Not Too Late




Disease Course





Allogeneic Stem Cell Transplant in Myelofibrosis: Unique Risks

Condition	Association with Post-Stem Cell Transplant Outcome
Anemia	Most MF Patients Anemic Not Prognostic
Thrombocytopenia	Cytopenic MF Worse Survival Worse Non-Relapse Mortality
Circulating blasts	Increased Relapse Risk in Accelerated Phase MF
Splenomegaly	Delayed Engraftment Graft Failure Increased Relapse Risk
Marrow fibrosis	Characteristic of MF Not Prognostic





Kröger N, Wolschke C, Gagelmann N. *Blood* 2023. DOI: [10.1182/blood.2023021218](https://doi.org/10.1182/blood.2023021218); Jungius et al. *Front Oncol.* 2023. DOI: [10.3389/fonc.2023.1205387](https://doi.org/10.3389/fonc.2023.1205387); Luther et al. *Bone Marrow Transplant.* 2023. DOI: [10.1038/s41409-023-01968-8](https://doi.org/10.1038/s41409-023-01968-8); Alchalby H, et al. *Bone Marrow Transplant.* 2016. DOI: [10.1038/bmt.2016.98](https://doi.org/10.1038/bmt.2016.98); Hernández-Boluda JC, et al. *Leukemia.* 2021. DOI: [10.1038/s41375-020-0815-z](https://doi.org/10.1038/s41375-020-0815-z).

Transplant is the Only Curative Therapy in Myelofibrosis – At a Cost



Lower Risk Myelofibrosis More Likely to Be Harmed by Early Bone Marrow Transplantation



MIPSS70 = mutation-enhanced international prognostic score system
MTSS = myelofibrosis transplant scoring system


MF Transplant Recommendations by EBMT/ELN International Working Group

Summary	Current MF Patient Selection for Allo-HCT
Patient Risk	Higher Risk Primary MF: DIPSS Intermediate-2 or High Risk MIPSS70+ High Risk and MTSS Low or Intermediate Risk
	Higher Risk Secondary MF: sMF Prognostic Model Score Intermediate-2 or High Risk
	Primary MF and DIPSS intermediate-1 or MIPSS70+ intermediate with low MTSS, accounting for patient preferences
Age	Patients >70 on Individual Basis
Timing	DIPSS Intermediate-2 and High-risk → Immediate DIPSS Low-risk or Intermediate-1-risk → Delayed





Kröger N, et al. Lancet Haematol. 2024 Jan;11(1):e62-e74. doi: 10.1016/S2352-3026(23)00305-8.

DIPSS = dynamic international prognostic scoring system

Estimating Transplant Risk in Myelofibrosis with Machine Learning



New Drugs are Meaningfully Advancing Therapeutic Responses Among Higher Risk Myelofibrosis



Pettit K et al. *Am Soc Clin Oncol Educ Book*. 2022. DOI: 10.1200/EDBK_349615; Rampal RK et al *Nat Med*. 2025 DOI: 10.1038/s41591-025-03572-3.

Conclusions

- Allogeneic SCT has unique challenges in MF
- Lower risk MF patients do not clearly benefit from transplant
- Higher risk MF patients are more likely to benefit
- Intermediate risk MF patients may benefit—transplant-related risk factors, shared decision making
- Numerous exciting drugs are around the corner in MF!
- Unclear how novel therapies, combinations may affect disease biology, modify transplant outcomes
- Therefore, delayed transplantation approach may benefit majority of MF patients